Tirzepatide has a similar side effect profile to semaglutide, with nausea and vomiting affecting up to 25% of people, but serious risks are rare.
🛡️ Safety Profile
Why This Rating
- Higher nausea and vomiting rates than semaglutide (33% vs 25%)
- No major unexpected harms, but limited long-term follow-up beyond 2 years
- More people discontinue due to GI side effects compared to other drugs
Safety Breakdown
Common side effects
Nausea occurs in ~33% of people, vomiting in ~11%—higher than semaglutide. GI upset is the main tolerability issue.
Serious safety concerns
Similar safety profile to semaglutide. No unexpected serious adverse events, but fewer total patient-years of exposure.
How often people stop
Higher GI burden leads to more treatment discontinuation compared to semaglutide. Roughly 10–15% stop due to tolerability.
How hard it is to manage
Subcutaneous injection once weekly, similar to semaglutide. Requires gradual dose escalation. No routine lab monitoring.
How certain we are long-term
Newer drug than semaglutide. Longest published follow-up is ~2 years. Long-term safety profile beyond 3 years is unknown.
Key Safety Flags
- Higher nausea/vomiting rates—affects about 1 in 3 people
- More people stop taking this drug due to GI side effects
- Very limited long-term safety data—only ~2 years published
- No confirmed heart benefit data yet (inferred from similar drugs)
Side Effects Overview
Understanding what side effects are common, how often they occur, and whether they're serious helps you make an informed decision.
During Weight Loss Testing
Population: Adults with obesity (BMI ≥27–30 depending on trial); no diabetes or type 2 diabetes; age 40–70; primarily White
Study Size: 6,693 participants
Duration: 12-104 weeks
Study context: Follow-up may be too short to fully assess long-term effects.
During Glycemic Control Testing
Population: Adults with type 2 diabetes; treatment-naïve to insulin-requiring; age 40–70; diverse ethnicities in SURPASS 6 and SURPASS-J
Study Size: 4,944 participants
Duration: 40-52 weeks
⚠️ What To Keep In Mind
All clinical evidence comes with limitations. Here's what matters for interpreting this drug's data:
- Nausea and vomiting occur more frequently with this drug than alternatives. Slower dose increase helps but does not eliminate the difference.
- All trials were funded by the drug manufacturer.
- It is unclear whether heart benefits come from weight loss, blood sugar control, or direct effects on the heart.
- The drug uses two mechanisms of action. We do not yet know whether both are necessary for its effect.
- No published evidence exists yet for this outcome.
- No published data on how the drug works after 1 year of use.
- Trial participants were primarily middle-aged and White. Results may not apply to younger, more diverse populations.
- Trial participants volunteered knowing the drug being tested. This may have selected for those more likely to tolerate it.
- Trials lasted up to 52 weeks, shorter than some competitor drugs tested for up to 2 years.
- Heart health trial is still in progress. Results will be available in late 2026 or 2027.
Common Questions
What are the side effects of tirzepatide?
Similar to semaglutide: nausea, vomiting, diarrhea, and constipation in 20-25% of people. Effects usually decrease after 2-3 weeks.
Is tirzepatide safe?
Tirzepatide is considered safe based on clinical trials, though long-term data (beyond 1-2 years) is still emerging.
What happens if I stop taking tirzepatide?
Weight loss may reverse over 6-12 months if you stop taking it without maintaining lifestyle changes.